MODERNA INC (1MRNA.MI) Stock Fundamental Analysis

BIT:1MRNA • US60770K1079

39.34 EUR
+3.67 (+10.27%)
Last: Feb 18, 2026, 07:00 PM
Overview Stock Chart Technical Analysis Fundamental Analysis Analyst Ratings Earnings Estimates Financials Ownership
Fundamental Rating

3

Overall 1MRNA gets a fundamental rating of 3 out of 10. We evaluated 1MRNA against 78 industry peers in the Biotechnology industry. The financial health of 1MRNA is average, but there are quite some concerns on its profitability. 1MRNA is quite expensive at the moment. It does show a decent growth rate.


Dividend Valuation Growth Profitability Health

2

1. Profitability

1.1 Basic Checks

  • 1MRNA had negative earnings in the past year.
  • In the past year 1MRNA has reported a negative cash flow from operations.
  • The reported net income has been mixed in the past 5 years: 1MRNA reported negative net income in multiple years.
  • The reported operating cash flow has been mixed in the past 5 years: 1MRNA reported negative operating cash flow in multiple years.
1MRNA.MI Yearly Net Income VS EBIT VS OCF VS FCF1MRNA.MI Yearly Net Income VS EBIT VS OCF VS FCFYearly Net Income VS EBIT VS OCF VS FCF 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 5B 10B

1.2 Ratios

  • 1MRNA has a Return On Assets of -25.68%. This is comparable to the rest of the industry: 1MRNA outperforms 57.69% of its industry peers.
  • Looking at the Return On Equity, with a value of -33.40%, 1MRNA is in the better half of the industry, outperforming 65.38% of the companies in the same industry.
Industry RankSector Rank
ROA -25.68%
ROE -33.4%
ROIC N/A
ROA(3y)-6.14%
ROA(5y)4.17%
ROE(3y)-7.66%
ROE(5y)6.83%
ROIC(3y)N/A
ROIC(5y)N/A
1MRNA.MI Yearly ROA, ROE, ROIC1MRNA.MI Yearly ROA, ROE, ROICYearly ROA, ROE, ROIC 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 20 -20 40 -40 60 80

1.3 Margins

  • The Gross Margin of 1MRNA (63.49%) is better than 60.26% of its industry peers.
  • In the last couple of years the Gross Margin of 1MRNA has declined.
  • The Profit Margin and Operating Margin are not available for 1MRNA so they could not be analyzed.
Industry RankSector Rank
OM N/A
PM (TTM) N/A
GM 63.49%
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y-6.55%
GM growth 5YN/A
1MRNA.MI Yearly Profit, Operating, Gross Margins1MRNA.MI Yearly Profit, Operating, Gross MarginsYearly Profit, Operating, Gross Margins 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 -200 -400 -600 -800

More info and screens

ROAROEROICOperating and Profit MarginShow most profitable peers

6

2. Health

2.1 Basic Checks

  • 1MRNA does not have a ROIC to compare to the WACC, probably because it is not profitable.
  • There is no outstanding debt for 1MRNA. This means it has a Debt/Equity and Debt/FCF ratio of 0 and it is amongst the best of the sector and industry.
1MRNA.MI Yearly Shares Outstanding1MRNA.MI Yearly Shares OutstandingYearly Shares Outstanding 2016 2017 2018 2019 2020 2021 2022 2023 2024 100M 200M 300M 400M
1MRNA.MI Yearly Total Debt VS Total Assets1MRNA.MI Yearly Total Debt VS Total AssetsYearly Total Debt VS Total Assets 2016 2017 2018 2019 2020 2021 2022 2023 2024 5B 10B 15B 20B 25B

2.2 Solvency

  • An Altman-Z score of 4.28 indicates that 1MRNA is not in any danger for bankruptcy at the moment.
  • Looking at the Altman-Z score, with a value of 4.28, 1MRNA is in the better half of the industry, outperforming 74.36% of the companies in the same industry.
  • 1MRNA has a Debt/Equity ratio of 0.00. This is a healthy value indicating a solid balance between debt and equity.
  • Looking at the Debt to Equity ratio, with a value of 0.00, 1MRNA belongs to the top of the industry, outperforming 89.74% of the companies in the same industry.
Industry RankSector Rank
Debt/Equity 0
Debt/FCF N/A
Altman-Z 4.28
ROIC/WACCN/A
WACC8.63%
1MRNA.MI Yearly LT Debt VS Equity VS FCF1MRNA.MI Yearly LT Debt VS Equity VS FCFYearly LT Debt VS Equity VS FCF 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 5B 10B 15B

2.3 Liquidity

  • A Current Ratio of 3.93 indicates that 1MRNA has no problem at all paying its short term obligations.
  • The Current ratio of 1MRNA (3.93) is better than 74.36% of its industry peers.
  • 1MRNA has a Quick Ratio of 3.73. This indicates that 1MRNA is financially healthy and has no problem in meeting its short term obligations.
  • With a decent Quick ratio value of 3.73, 1MRNA is doing good in the industry, outperforming 75.64% of the companies in the same industry.
Industry RankSector Rank
Current Ratio 3.93
Quick Ratio 3.73
1MRNA.MI Yearly Current Assets VS Current Liabilites1MRNA.MI Yearly Current Assets VS Current LiabilitesYearly Current Assets VS Current Liabilites 2016 2017 2018 2019 2020 2021 2022 2023 2024 5B 10B 15B

More info and screens

WACCDebt/EquityHow to determine the health of a companyAltman-Z scoreShow peers with great health

4

3. Growth

3.1 Past

  • The Earnings Per Share has grown by an impressive 21.66% over the past year.
EPS 1Y (TTM)21.66%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%27.49%
Revenue 1Y (TTM)N/A
Revenue growth 3YN/A
Revenue growth 5YN/A
Sales Q2Q%-29.81%

3.2 Future

  • Based on estimates for the next years, 1MRNA will show a very strong growth in Earnings Per Share. The EPS will grow by 21.01% on average per year.
  • Based on estimates for the next years, 1MRNA will show a very strong growth in Revenue. The Revenue will grow by 29.07% on average per year.
EPS Next Y2.17%
EPS Next 2Y13.98%
EPS Next 3Y16.77%
EPS Next 5Y21.01%
Revenue Next Year6.38%
Revenue Next 2Y10.38%
Revenue Next 3Y19.5%
Revenue Next 5Y29.07%

3.3 Evolution

1MRNA.MI Yearly Revenue VS Estimates1MRNA.MI Yearly Revenue VS EstimatesYearly Revenue VS Estimates 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 2026 2027 2028 2029 2030 2031 2032 2033 5B 10B 15B
1MRNA.MI Yearly EPS VS Estimates1MRNA.MI Yearly EPS VS EstimatesYearly EPS VS Estimates 2018 2019 2020 2021 2022 2023 2024 2025 2026 2027 2028 2029 2030 2031 2032 2033 0 10 -10 20

More info and screens

Find the best growth stocksShow best growing peers

0

4. Valuation

4.1 Price/Earnings Ratio

  • 1MRNA reported negative earnings for the last year, which makes the Price/Earnings Ratio negative.
  • Also next year 1MRNA is expected to report negative earnings again, which makes the also the Forward Price/Earnings Ratio negative.
Industry RankSector Rank
PE N/A
Fwd PE N/A
1MRNA.MI Price Earnings VS Forward Price Earnings1MRNA.MI Price Earnings VS Forward Price Earnings ChartPrice Earnings - Forward Price Earnings PE FPE 0 20 40 60

4.2 Price Multiples

Industry RankSector Rank
P/FCF N/A
EV/EBITDA N/A
1MRNA.MI Per share data1MRNA.MI EPS, Sales, OCF, FCF, BookValue per sharePer Share Data Per Share 0 5 -5 10 15 20

4.3 Compensation for Growth

  • A more expensive valuation may be justified as 1MRNA's earnings are expected to grow with 16.77% in the coming years.
PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y13.98%
EPS Next 3Y16.77%

More info and screens

Price/EarningsPrice/FCFFCF per shareEV/EBITDAPEG RATIOShow best valued peers

0

5. Dividend

5.1 Amount

  • No dividends for 1MRNA!.
Industry RankSector Rank
Dividend Yield 0%

More info and screens

Find the best dividend stocksShow peers with best dividend

MODERNA INC

BIT:1MRNA (2/18/2026, 7:00:00 PM)

39.34

+3.67 (+10.27%)

Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryBiotechnology
Earnings (Last)02-13
Earnings (Next)04-29
Inst Owners71.72%
Inst Owner ChangeN/A
Ins Owners2.73%
Ins Owner ChangeN/A
Market Cap15.37B
Revenue(TTM)N/A
Net Income(TTM)-3.12B
Analysts56
Price Target34.33 (-12.74%)
Short Float %N/A
Short RatioN/A
Dividend
Industry RankSector Rank
Dividend Yield 0%
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)2
Avg EPS beat(2)52.94%
Min EPS beat(2)29.6%
Max EPS beat(2)76.27%
EPS beat(4)3
Avg EPS beat(4)30.21%
Min EPS beat(4)-6.26%
Max EPS beat(4)76.27%
EPS beat(8)7
Avg EPS beat(8)49.68%
EPS beat(12)9
Avg EPS beat(12)9.25%
EPS beat(16)12
Avg EPS beat(16)10.78%
Revenue beat(2)2
Avg Revenue beat(2)17.81%
Min Revenue beat(2)12.36%
Max Revenue beat(2)23.26%
Revenue beat(4)3
Avg Revenue beat(4)8.94%
Min Revenue beat(4)-0.3%
Max Revenue beat(4)23.26%
Revenue beat(8)7
Avg Revenue beat(8)29.87%
Revenue beat(12)10
Avg Revenue beat(12)27.21%
Revenue beat(16)13
Avg Revenue beat(16)22.97%
PT rev (1m)15.27%
PT rev (3m)-4.07%
EPS NQ rev (1m)2.63%
EPS NQ rev (3m)4.35%
EPS NY rev (1m)0.81%
EPS NY rev (3m)18.24%
Revenue NQ rev (1m)1.81%
Revenue NQ rev (3m)-11.93%
Revenue NY rev (1m)0.36%
Revenue NY rev (3m)-0.52%
Valuation
Industry RankSector Rank
PE N/A
Fwd PE N/A
P/S 8.14
P/FCF N/A
P/OCF N/A
P/B 1.95
P/tB 1.97
EV/EBITDA N/A
EPS(TTM)-6.15
EYN/A
EPS(NY)-6.01
Fwd EYN/A
FCF(TTM)-5.76
FCFYN/A
OCF(TTM)-4.28
OCFYN/A
SpS4.83
BVpS20.19
TBVpS19.98
PEG (NY)N/A
PEG (5Y)N/A
Graham NumberN/A
Profitability
Industry RankSector Rank
ROA -25.68%
ROE -33.4%
ROCE N/A
ROIC N/A
ROICexc N/A
ROICexgc N/A
OM N/A
PM (TTM) N/A
GM 63.49%
FCFM N/A
ROA(3y)-6.14%
ROA(5y)4.17%
ROE(3y)-7.66%
ROE(5y)6.83%
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexgc growth 3YN/A
ROICexgc growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y-6.55%
GM growth 5YN/A
F-Score2
Asset Turnover0.18
Health
Industry RankSector Rank
Debt/Equity 0
Debt/FCF N/A
Debt/EBITDA N/A
Cap/Depr 329.33%
Cap/Sales 30.69%
Interest Coverage N/A
Cash Conversion N/A
Profit Quality N/A
Current Ratio 3.93
Quick Ratio 3.73
Altman-Z 4.28
F-Score2
WACC8.63%
ROIC/WACCN/A
Cap/Depr(3y)261.63%
Cap/Depr(5y)224.68%
Cap/Sales(3y)14.96%
Cap/Sales(5y)10.95%
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)21.66%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%27.49%
EPS Next Y2.17%
EPS Next 2Y13.98%
EPS Next 3Y16.77%
EPS Next 5Y21.01%
Revenue 1Y (TTM)N/A
Revenue growth 3YN/A
Revenue growth 5YN/A
Sales Q2Q%-29.81%
Revenue Next Year6.38%
Revenue Next 2Y10.38%
Revenue Next 3Y19.5%
Revenue Next 5Y29.07%
EBIT growth 1Y-46.28%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next Year19.26%
EBIT Next 3Y15.27%
EBIT Next 5Y17.94%
FCF growth 1Y-0.23%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y4.81%
OCF growth 3YN/A
OCF growth 5YN/A

MODERNA INC / 1MRNA.MI FAQ

Can you provide the ChartMill fundamental rating for MODERNA INC?

ChartMill assigns a fundamental rating of 3 / 10 to 1MRNA.MI.


What is the valuation status for 1MRNA stock?

ChartMill assigns a valuation rating of 0 / 10 to MODERNA INC (1MRNA.MI). This can be considered as Overvalued.


Can you provide the profitability details for MODERNA INC?

MODERNA INC (1MRNA.MI) has a profitability rating of 2 / 10.


How financially healthy is MODERNA INC?

The financial health rating of MODERNA INC (1MRNA.MI) is 6 / 10.


What is the expected EPS growth for MODERNA INC (1MRNA.MI) stock?

The Earnings per Share (EPS) of MODERNA INC (1MRNA.MI) is expected to grow by 2.17% in the next year.